In Roche Molecular Systems, Inc., v. Cepheid, [2017-1690] (October 9, 2018), the Federal Circuit affirmed summary judgment of invalidity of claims of U.S. Patent No. 5,643,723 as directed to patent ineligible subject matter. The ’723 patent is directed to methods for … Continue reading Primers and the Use of Naturally Occurring Position-Specific Signature Nucleotides are Patent Ineligible